Literature DB >> 16510574

7,12-dimethylbenz(a)anthracene treatment of a c-rel mouse mammary tumor cell line induces epithelial to mesenchymal transition via activation of nuclear factor-kappaB.

Sangmin Ryan Shin1, Nuria Sánchez-Velar, David H Sherr, Gail E Sonenshein.   

Abstract

The aberrant expression of the nuclear factor-kappaB (NF-kappaB) c-Rel subunit that occurs in many human breast cancers can play a causal role in tumorigenesis as judged by findings with a mouse mammary tumor virus (MMTV)-c-rel transgenic mouse model, in which 31.6% of mice developed one or more mammary tumors after a long latency. Interestingly, none of the cell lines established from the mammary tumors grew in soft agar. To begin to test the hypothesis that a prototypic carcinogen insult can promote a more invasive, mesenchymal phenotype, a cell line established from a MMTV-c-rel mammary tumor rel-3983 was treated in culture with the polycyclic aromatic hydrocarbon 7,12-dimethylbenz(a)anthracene (DMBA; rel-3983D cells) or DMSO vehicle (rel-3983V cells). Rel-3983D cells displayed an increased rate of proliferation, displayed growth to a higher cell density, and acquired the ability to grow in soft agar and in Matrigel compared with the parental rel-3983 or vehicle-treated rel-3983V cells. Consistent with a more mesenchymal phenotype, rel-3983D cells showed loss of E-cadherin expression as judged by immunofluorescence microscopy. Compared with control cells, rel-3983D displayed increased NF-kappaB binding and higher levels of the NF-kappaB transactivating subunits c-Rel, RelA, and RelB, which seemed functional as judged by induction of c-Myc and vimentin, products of two NF-kappaB target genes. Ectopic expression of a super repressor mutant of IkappaB-alpha reduced rel-3983D cell growth and invasive morphology in Matrigel, confirming the role of NF-kappaB in epithelial to mesenchymal transition (EMT). Thus, DMBA treatment of c-Rel-transformed mammary tumor cells in culture is shown here for the first time to result in EMT via activation of NF-kappaB. The aberrant c-Rel expression present in most human breast cancers suggests that this mechanism may play an important role in carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16510574     DOI: 10.1158/0008-5472.CAN-05-3056

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Epithelial-mesenchymal transition: a new target in anticancer drug discovery.

Authors:  Fabrizio Marcucci; Giorgio Stassi; Ruggero De Maria
Journal:  Nat Rev Drug Discov       Date:  2016-01-29       Impact factor: 84.694

2.  In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo.

Authors:  Ashley J Parks; Michael P Pollastri; Mark E Hahn; Elizabeth A Stanford; Olga Novikov; Diana G Franks; Sarah E Haigh; Supraja Narasimhan; Trent D Ashton; Timothy G Hopper; Dmytro Kozakov; Dimitri Beglov; Sandor Vajda; Jennifer J Schlezinger; David H Sherr
Journal:  Mol Pharmacol       Date:  2014-08-26       Impact factor: 4.436

Review 3.  Regulation of constitutive and inducible AHR signaling: complex interactions involving the AHR repressor.

Authors:  Mark E Hahn; Lenka L Allan; David H Sherr
Journal:  Biochem Pharmacol       Date:  2008-09-20       Impact factor: 5.858

4.  The p53 homologue DeltaNp63alpha interacts with the nuclear factor-kappaB pathway to modulate epithelial cell growth.

Authors:  Kathryn E King; Roshini M Ponnamperuma; Clint Allen; Hai Lu; Praveen Duggal; Zhong Chen; Carter Van Waes; Wendy C Weinberg
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

5.  Interaction of aryl hydrocarbon receptor and NF-κB subunit RelB in breast cancer is associated with interleukin-8 overexpression.

Authors:  Christoph Franz Adam Vogel; Wen Li; Dalei Wu; Jamie K Miller; Colleen Sweeney; Gwendal Lazennec; Yasuko Fujisawa; Fumio Matsumura
Journal:  Arch Biochem Biophys       Date:  2011-05-26       Impact factor: 4.013

Review 6.  The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis.

Authors:  Josiah Ochieng; Gladys N Nangami; Olugbemiga Ogunkua; Isabelle R Miousse; Igor Koturbash; Valerie Odero-Marah; Lisa J McCawley; Pratima Nangia-Makker; Nuzhat Ahmed; Yunus Luqmani; Zhenbang Chen; Silvana Papagerakis; Gregory T Wolf; Chenfang Dong; Binhua P Zhou; Dustin G Brown; Anna Maria Colacci; Roslida A Hamid; Chiara Mondello; Jayadev Raju; Elizabeth P Ryan; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Amedeo Amedei; Rabeah Al-Temaimi; Fahd Al-Mulla; William H Bisson; Sakina E Eltom
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

7.  Dynamic expression of a LEF-EGFP Wnt reporter in mouse development and cancer.

Authors:  Nicolas Currier; Kathleen Chea; Mirka Hlavacova; Daniel J Sussman; David C Seldin; Isabel Dominguez
Journal:  Genesis       Date:  2010-03       Impact factor: 2.487

8.  TAp63 is a transcriptional target of NF-kappaB.

Authors:  Junfeng Wu; Johann Bergholz; Jinin Lu; Gail E Sonenshein; Zhi-Xiong Jim Xiao
Journal:  J Cell Biochem       Date:  2010-03-01       Impact factor: 4.429

9.  Follistatin-like protein 1 promotes arthritis by up-regulating IFN-gamma.

Authors:  Suzanne D Clutter; David C Wilson; Anthony D Marinov; Raphael Hirsch
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

10.  Inhibition of Epithelial-to-Mesenchymal Transition (EMT) in Cancer by Nitric Oxide: Pivotal Roles of Nitrosylation of NF-κB, YY1 and Snail.

Authors:  Benjamin Bonavida; Stavroula Baritaki
Journal:  For Immunopathol Dis Therap       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.